Dendritic cell immunotherapy for stage IV melanoma
/in International Publications, Malignant MelanomaSelected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses
/in International Publications, MicronutrientsImmunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines
/in Colorectal Cancer, International PublicationsApoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart
/in Hypernephroma, International PublicationsPhase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
/in Hypernephroma, International PublicationsMonocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis
/in International Publications, Malignant LymphomaRegression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in Apc(Min/+) mice
/in Dendritic Cells, Hyperthermia, International PublicationsLong-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial
/in Cervical Cancer, International PublicationsInduction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination
/in International Publications, Malignant Lymphoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer